Nat Commun:全基因组分析揭示鼻咽癌中的病毒-宿主作用

2021-07-09 xiaozeng MedSci原创

鼻咽癌(NPC)是一种病因复杂的肿瘤,具有流行病学、组织学和病毒特征的独特组合。

鼻咽癌(NPC)是一种病因复杂的肿瘤,具有流行病学、组织学和病毒特征的独特组合。每年约有129,000名新诊断NPC患者,其中东南亚、北非和北美北部地区的因纽特人的发病率最高。

NPC的特征表现为低分化状态的恶性上皮细胞位于复杂的微环境中,在该微环境中存在淋巴细胞的大量浸润,这也导致出现具有明显炎症表型的淋巴上皮瘤。


爱泼斯坦 - 巴尔病毒(EBV)是一种广泛存在于人群中的疱疹病毒,既往研究显示,恶性细胞中均呈现EBV阳性。B淋巴细胞中EBV的持续潜伏感染与几种B细胞恶性肿瘤具有因果关系,包括伯基特淋巴瘤、霍奇金病、艾滋病相关淋巴瘤、弥漫性大B细胞淋巴瘤,以及相关上皮肿瘤(如NPC和胃癌等)。

然而,在NPC的发生发展过程中,EBV的感染和获得性遗传改变之间的相互作用尚不明确。


在该研究中,研究人员对70个NPC样本进行全基因组分析,通过将肿瘤细胞的全基因组测序(WGS)数据与EBV的癌基因表达情况相结合,以揭示肿瘤发生过程中细胞-病毒之间相互作用的相关机制。

NPC的全基因组景观

结果显示,在90%的NPC中,基因组突变伴随着EBV编码的LMP1的表达能够诱导组成型NF-κB的激活。研究人员发现,类似的体细胞突变和病毒基因表达能够破坏79%的先天免疫和47%的适应性免疫,尽管其具有促炎表型,但NPC可逃避免疫监视。


此外,损害TGFBR2的基因组突变能够促进肿瘤的发生发展并稳定肿瘤细胞中的EBV感染状态。CDKN2A/CDKN2B缺失断点的精细定位显示,32-34%的NPC中存在纯合的MTAP缺失,这对MAT2A抑制作用具有显著的敏感性。

鼻咽癌的全基因组水平常改变的相关癌症通路

总而言之,该研究结果表明,NPC是一种均质的NF-κB驱动和受免疫保护的癌症,同时也揭示了NPC的潜在的药物治疗靶标。


原始出处:

Bruce, J.P., To, KF., Lui, V.W.Y. et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape. Nat Commun 12, 4193 (07 July 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1719812, encodeId=dfbc1e198126a, content=<a href='/topic/show?id=d57a29400ba' target=_blank style='color:#2F92EE;'>#全基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29400, encryptionId=d57a29400ba, topicName=全基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jul 15 00:55:53 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736164, encodeId=92201e3616471, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon May 23 16:55:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885291, encodeId=39c81885291db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 08 22:55:53 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088062, encodeId=6eda2088062af, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jan 07 17:55:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404776, encodeId=3b3d1404e765c, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546558, encodeId=879f1546558e6, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1719812, encodeId=dfbc1e198126a, content=<a href='/topic/show?id=d57a29400ba' target=_blank style='color:#2F92EE;'>#全基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29400, encryptionId=d57a29400ba, topicName=全基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jul 15 00:55:53 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736164, encodeId=92201e3616471, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon May 23 16:55:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885291, encodeId=39c81885291db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 08 22:55:53 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088062, encodeId=6eda2088062af, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jan 07 17:55:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404776, encodeId=3b3d1404e765c, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546558, encodeId=879f1546558e6, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1719812, encodeId=dfbc1e198126a, content=<a href='/topic/show?id=d57a29400ba' target=_blank style='color:#2F92EE;'>#全基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29400, encryptionId=d57a29400ba, topicName=全基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jul 15 00:55:53 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736164, encodeId=92201e3616471, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon May 23 16:55:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885291, encodeId=39c81885291db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 08 22:55:53 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088062, encodeId=6eda2088062af, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jan 07 17:55:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404776, encodeId=3b3d1404e765c, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546558, encodeId=879f1546558e6, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2022-03-08 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1719812, encodeId=dfbc1e198126a, content=<a href='/topic/show?id=d57a29400ba' target=_blank style='color:#2F92EE;'>#全基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29400, encryptionId=d57a29400ba, topicName=全基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jul 15 00:55:53 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736164, encodeId=92201e3616471, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon May 23 16:55:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885291, encodeId=39c81885291db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 08 22:55:53 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088062, encodeId=6eda2088062af, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jan 07 17:55:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404776, encodeId=3b3d1404e765c, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546558, encodeId=879f1546558e6, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2022-01-07 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1719812, encodeId=dfbc1e198126a, content=<a href='/topic/show?id=d57a29400ba' target=_blank style='color:#2F92EE;'>#全基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29400, encryptionId=d57a29400ba, topicName=全基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jul 15 00:55:53 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736164, encodeId=92201e3616471, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon May 23 16:55:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885291, encodeId=39c81885291db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 08 22:55:53 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088062, encodeId=6eda2088062af, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jan 07 17:55:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404776, encodeId=3b3d1404e765c, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546558, encodeId=879f1546558e6, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=)]
    2021-07-10 wincls
  6. [GetPortalCommentsPageByObjectIdResponse(id=1719812, encodeId=dfbc1e198126a, content=<a href='/topic/show?id=d57a29400ba' target=_blank style='color:#2F92EE;'>#全基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29400, encryptionId=d57a29400ba, topicName=全基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jul 15 00:55:53 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736164, encodeId=92201e3616471, content=<a href='/topic/show?id=e5504182238' target=_blank style='color:#2F92EE;'>#基因组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41822, encryptionId=e5504182238, topicName=基因组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e5234086891, createdName=xue8613, createdTime=Mon May 23 16:55:53 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885291, encodeId=39c81885291db, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 08 22:55:53 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088062, encodeId=6eda2088062af, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jan 07 17:55:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404776, encodeId=3b3d1404e765c, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546558, encodeId=879f1546558e6, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Sat Jul 10 15:55:53 CST 2021, time=2021-07-10, status=1, ipAttribution=)]

相关资讯

ASCO 2021期间马骏团队再发鼻咽癌重磅研究

该试验对局部晚期鼻咽癌患者接受根治性同步放化疗后继续接受卡培他滨节拍辅助化疗的疗效与安全性进行了研究。

免疫药物联合化疗,晚期鼻咽癌患者可获更长生存期

随着CAPTAIN-1ST研究结果的揭晓以及一线治疗适应症的获批,卡瑞利珠单抗联合GP化疗毫无疑问已成为复发/转移鼻咽癌的一线优选方案。未来该方案写入国际指南、影响全球鼻咽癌的治疗也是指日可待。

Lancet oncol:卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法

卡瑞珠单抗组联合吉西他滨和顺铂或可成为复发性或转移性鼻咽癌患者的新标准一线治疗方案

2021 ASCO:鼻咽癌领域中国之声

去年中国共有12项研究入选ASCO年会进行口头报告,创造历史。2021年,我们再次见证奇迹:今年共有20项来自中国学者的研究获得2021 ASCO年会口头报告发。

Nat Commun:综合药物基因组学揭示鼻咽癌亚型特异性治疗反应

鼻咽癌(NPC)作为一种恶性头颈癌,其发病率很高